MCMarcelo Leite Vieira Costa

Marcelo Leite Vieira Costa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcelo Leite Vieira Costa has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • José Wilson Benevides de Mesquita Neto

    Departamento de Oncologia Digestiva. Instituto do Câncer do Ceará - Hospital Haroldo Juaçaba (HHJ-ICC). Fortaleza/CE, Brasil, Departamento de Oncologia Digestiva, Instituto do Câncer do Ceará, Hospital Haroldo Juaçaba, Fortaleza CE , Brasil

    2 shared publications
  • Davy Bruno Machado

    Departamento de Oncologia Digestiva. Instituto do Câncer do Ceará - Hospital Haroldo Juaçaba (HHJ-ICC). Fortaleza/CE, Brasil, Departamento de Oncologia Digestiva, Instituto do Câncer do Ceará, Hospital Haroldo Juaçaba, Fortaleza CE , Brasil

    1 shared publication
  • Diego Fonseca Cordeiro

    Escola Cearense de Oncologia. Instituto do Câncer do Ceará - Hospital Haroldo Juaçaba (HHJ-ICC). Fortaleza/CE, Brasil, Escola Cearense de Oncologia, Instituto do Câncer do Ceará, Hospital Haroldo Juaçaba, Fortaleza CE , Brasil

    1 shared publication
  • Dárcio Jânio Macedo

    Programa de Cancerologia Cirúrgica. Instituto do Câncer do Ceará - Hospital Haroldo Juaçaba (HHJ-ICC). Fortaleza/CE, Brasil, Instituto do Câncer do Ceará, Hospital Haroldo Juaçaba, Fortaleza CE , Brasil

    1 shared publication
  • Eurivaldo Valente de Brito

    Escola Cearense de Oncologia. Instituto do Câncer do Ceará - Hospital Haroldo Juaçaba (HHJ-ICC). Fortaleza/CE, Brasil, Escola Cearense de Oncologia, Instituto do Câncer do Ceará, Hospital Haroldo Juaçaba, Fortaleza CE , Brasil

    1 shared publication
  • Gerly Anne Castro Brito

    Department of Physiology and Pharmacology, Faculty of Medicine Federal University of Ceará Fortaleza Ceará Brazil

    1 shared publication

Latest Publications

  • Open Access

    Extended pelvic resections for the treatment of locally advanced and recurrent anal canal and colorectal cancer: technical aspects and morbimortality predictors aftet 24 consecutive cases

    by José Wilson Benevides de Mesquita Neto, Davy Bruno Machado, Dárcio Jânio Macedo, Diego Fonseca Cordeiro, Eurivaldo Valente de Brito, Marcelo Leite Vieira Costa

    Objective: to evaluate the profile of morbidity and mortality and its predictors related to extensive pelvic resections, including pelvic exenteration, to optimize the selection of patients and achieve better surgical results. Methods: we performed 24 major resections for anorectal pelvic malignancy from 2008 to 2015 in the Instituto do Câncer do Ceará. The factors analyzed included age, weight loss, resected organs, total versus posterior exenteration, angiolymphatic and perineural invasion, lymph node metastasis and overall and disease-free survival. Results: the median age was 57 years and the mean follow-up was ten months. Overall morbidity was 45.8%, with five (20.8%) serious complications. There were no deaths in the first 30 postoperative days. The median overall survival was 39.5 months, and disease-free survival, 30.7 months. Concomitant resection of the bladder was an isolated prognostic factor for higher risk of complications (87.5% vs. 26.7%, p = 0.009). Angiolymphatic invasion and lymph node metastasis did not reach significance with respect to disease-free survival. Conclusion: treatment of advanced anorectal tumors is challenging, often requiring combined resections, such as cystectomy and sacrectomy, and complex reconstructions. The magnitude of the operation still carries a high morbidity rate, but is a procedure considered safe and feasible, with a low mortality and adequate locoregional tumor control when performed in referral centers.


  • Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model

    by Marcelo Leite Vieira Costa, Roberto César Pereira Lima-Júnior, Karoline Sabóia Aragão, Raul Pinheiro Medeiros, Raphael Dias Marques-Neto, Lucas de Sá Grassi, Leandro Linhares Leite, Lorena Guimaraes Nunes, José Wilson Benevides de Mesquita Neto, Gerly Anne de Castro Brito, et al.

    Nonalcoholic steatohepatitis (NASH) has been associated with irinotecan (IRI)-based cancer chemotherapy regimens. The purpose of this study was to propose and test a consistent model of IRI-induced NASH, filling a gap in the medical literature. Swiss male mice were distributed in groups (n = 8) and injected with saline (5 mL/kg, i.p.; control) or IRI (25, 50, 75 or 100 mg/kg, i.p.) thrice a week for 7 weeks. Blood samples were collected to measure the serum concentrations of proteins, alanine and aspartate aminotransferases (ALT and AST). Each week animals were euthanized, and the livers were submitted to myeloperoxidase (MPO) assay, lipid dosage, immunohistochemistry for inducible nitric oxide synthase (iNOS), TNF-α and interleukin-1β (IL-1β), and histopathological analysis. Survival rates were also determined. Mice treated with IRI had a significantly (p < 0.05) lower survival rate than controls and time- and dose-dependent body weight loss. ALT and AST plasma levels increased in relation to controls only in mice receiving IRI 50 mg/kg (p < 0.05). The histopathological features characteristic of NASH was observed, including steatosis, lobular neutrophil infiltration and ballooning hepatocytic degeneration. Additional findings included increased MPO, lipid accumulation, portal neutrophil infiltration, IL-1β and iNOS expression and fibrosis in liver tissues and low serum protein levels compared to controls. This is the first report of a consistent model of IRI-induced NASH capable of mimicking clinical findings.